Serguei Nabirotchkin

An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A

Shahram Attarian, Jean‐Michel Vallat, Laurent Magy et al. · Orphanet Journal of Rare Diseases · 2014 · 124 citations · Full text

Polytherapy with a combination of three repurposed drugs (PXT3003) down-regulates Pmp22 over-expression and improves myelination, axonal and functional parameters in models of CMT1A neuropathy

Ilya Chumakov, Aude Milet, Nathalie Cholet et al. · Orphanet Journal of Rare Diseases · 2014 · 105 citations · Full text

Combining two repurposed drugs as a promising approach for Alzheimer's disease therapy

Ilya Chumakov, Serguei Nabirotchkin, Nathalie Cholet et al. · Scientific Reports · 2015 · 64 citations · Full text

Combination of acamprosate and baclofen as a promising therapeutic approach for Parkinson’s disease

Rodolphe Hajj, Aude Milet, Damien Toulorge et al. · Scientific Reports · 2015 · 57 citations · Full text

Early short-term PXT3003 combinational therapy delays disease onset in a transgenic rat model of Charcot-Marie-Tooth disease 1A (CMT1A)

Thomas Prukop, Jan Stenzel, Stephanie Wernick et al. · PLoS ONE · 2019 · 48 citations · Full text

Gene Therapies, Charcot-marie-tooth Disease, Medicine +15